MBX Biosciences, Inc. announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO). Karen Basbaum is an accomplished biopharmaceutical executive with more than two decades of experience in corporate strategy, business development, and value-creating transactions across the biotechnology and pharmaceutical industries. Prior to joining MBX Biosciences, Ms. Basbaum served as Senior Vice President of Business Development at Poseida Therapeutics, where she was a member of the Executive Committee and led strategic partnerships and corporate transactions totaling more than $10 billion in potential value, and she played a key role in the company?s sale to Roche for up to $1.5 billion.
Earlier in her career, Ms. Basbaum held senior business development leadership roles at DNAtrix, Dauntless Pharmaceuticals, and Elcelyx Therapeutics, where she led partnering strategies, financings, and strategic initiatives. She also served as Director of Business Development at Amylin Pharmaceuticals, contributing to the company?s $7 billion acquisition by Bristol Myers Squibb. Ms. Basbaum began her career in scientific research roles at Celgene and Abbott Laboratories.
She holds an MBA from the University of California, Irvine; an M.S. in Organic Chemistry from Rensselaer Polytechnic Institute; and dual B.S. degrees in Chemistry and Biology (honors) from the University of North Dakota.
